Immunogenicity of a recombinant hepatitis B vaccine in hemophiliacs.
Yeast-recombinant vaccines against hepatitis B virus (HBV) are now available, but there is no information about whether or not they are immunogenic in patients with hemophilia and other congenital bleeding disorders. Twenty micrograms of a recombinant vaccine expressing the adw serotype of the hepatitis B surface antigen (HBsAg) were given to 41 patients negative for HBV markers and again after 1 and 6 months. Ten percent of the vaccinees had anti-hepatitis B surface antibody (anti-HBs) responses, with titers of 10 mIU/ml or more, 1 month after the first dose of vaccine. The percentage of anti-HBs-positive patients increased to 54% after the second dose and to 98% after the third dose, with only one non-responder. Hence, the recombinant vaccine was immunogenic, with percentages of seroconversion and anti-HBs titers similar to those achieved with plasma-derived vaccines.
Mannucci
P M
PM
Study Group of the Italian Hemophilia Foundation, Milan, Italy.
Gringeri
A
A
Morfini
M
M
De Biasi
R
R
Tirindelli
M C
MC
Tamponi
G
G
Baudo
F
F
Carnelli
V
V
Ciavarella
N
N
Colombo
M
M
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D000917:Antibody Formation; D002648:Child; D002675:Child, Preschool; D006467:Hemophilia A / Q000276:immunology*; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D008875:Middle Aged; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines